1647P Dabrafenib/trametinib versus encorafenib/binimetinib in BRAF-mutant metastatic melanoma: A real-world propensity score matched survival analysis. - Garitaonaindía Díaz, Y.; Khan, S.; Friis, R.B.; Petersen, S.K.; Borch, T.H.; Ruhlmann, C.H.; Guldbrandt, L.M.; Luczak, A.A.; Schmidt, H.; Bastholt, L.; Svane, I.M.; Donia, M.; et al. (Annals of Oncology, 2025)